263 related articles for article (PubMed ID: 15793363)
1. Cytomegalovirus viremia, mortality, and end-organ disease among patients with AIDS receiving potent antiretroviral therapies.
Wohl DA; Zeng D; Stewart P; Glomb N; Alcorn T; Jones S; Handy J; Fiscus S; Weinberg A; Gowda D; van der Horst C
J Acquir Immune Defic Syndr; 2005 Apr; 38(5):538-44. PubMed ID: 15793363
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus viremia in Thai HIV-infected patients on antiretroviral therapy: prevalence and associated mortality.
Durier N; Ananworanich J; Apornpong T; Ubolyam S; Kerr SJ; Mahanontharit A; Ferradini L; Ruxrungtham K; Avihingsanon A
Clin Infect Dis; 2013 Jul; 57(1):147-55. PubMed ID: 23511301
[TBL] [Abstract][Full Text] [Related]
3. Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030.
Wohl DA; Kendall MA; Andersen J; Crumpacker C; Spector SA; Feinberg J; Alston-Smith B; Owens S; Chafey S; Marco M; Maxwell S; Lurain N; Jabs D; Benson C; Keiser P; Jacobson MA;
HIV Clin Trials; 2009; 10(3):143-52. PubMed ID: 19632953
[TBL] [Abstract][Full Text] [Related]
4. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.
Salmon-Céron D; Mazeron MC; Chaput S; Boukli N; Senechal B; Houhou N; Katlama C; Matheron S; Fillet AM; Gozlan J; Leport C; Jeantils V; Freymuth F; Costagliola D
AIDS; 2000 May; 14(8):1041-9. PubMed ID: 10853987
[TBL] [Abstract][Full Text] [Related]
5. Distribution and determinants of cytomegalovirus induced end organ disease/s among people living with HIV/AIDS in a poor resource setting: observation from India.
Chakraborty A; Mahapatra T; Mahapatra S; Ansari S; Siddhanta S; Banerjee S; Banerjee D; Sarkar RN; Guha SK; Chakraborty N
PLoS One; 2015; 10(2):e0117466. PubMed ID: 25679798
[TBL] [Abstract][Full Text] [Related]
6. [Predictors of progression and death in patients with advanced HIV infection in the era of highly active antiretroviral therapy].
Reus S; Portilla J; Gimeno A; Sánchez-Payá J; García-Henarejos JA; Martínez-Madrid O; Usó J; Roca B; Galindo MJ; López-Aldeguer J
Enferm Infecc Microbiol Clin; 2004 Mar; 22(3):142-9. PubMed ID: 14987534
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus viremia as a risk factor for mortality prior to antiretroviral therapy among HIV-infected gold miners in South Africa.
Fielding K; Koba A; Grant AD; Charalambous S; Day J; Spak C; Wald A; Huang ML; Corey L; Churchyard GJ
PLoS One; 2011; 6(10):e25571. PubMed ID: 22022413
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy.
Weinberg A; Tierney C; Kendall MA; Bosch RJ; Patterson-Bartlett J; Erice A; Hirsch MS; Polsky B;
J Infect Dis; 2006 Feb; 193(4):488-93. PubMed ID: 16425127
[TBL] [Abstract][Full Text] [Related]
9. Low frequency of cytomegalovirus (CMV) disease despite high prevalence of CMV viraemia in patients with advanced HIV infection: a clinical and immunological 48-week follow-up study.
Albasanz-Puig A; Suanzes P; Esperalba J; Fernández C; Sellarès-Nadal J; Torrella A; Planas B; Segura A; Burgos J; Ribera E; Cañas-Ruano E; García JN; Navarro J; Curran A; Len Ó; Falcó V
HIV Med; 2021 Sep; 22(8):682-689. PubMed ID: 33998115
[TBL] [Abstract][Full Text] [Related]
10. Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy.
Deayton JR; Prof Sabin CA; Johnson MA; Emery VC; Wilson P; Griffiths PD
Lancet; 2004 Jun; 363(9427):2116-21. PubMed ID: 15220032
[TBL] [Abstract][Full Text] [Related]
11. Qualitative and quantitative PCR measures of cytomegalovirus in patients with advanced HIV infection who require transfusions.
Para MF; Kalish LA; Collier AC; Pollard RB; Kumar PN; Mintz L; Wallach FR; Drew WL;
J Acquir Immune Defic Syndr; 2001 Apr; 26(4):320-5. PubMed ID: 11317072
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the efficacy and safety of pre-emptive anti-cytomegalovirus (CMV) therapy in HIV-infected patients with CMV viraemia.
Mattioni S; Pavie J; Porcher R; Scieux C; Denis B; De Castro N; Simon F; Molina JM
Int J STD AIDS; 2015 Apr; 26(5):306-12. PubMed ID: 24845948
[TBL] [Abstract][Full Text] [Related]
13. Influence of highly active antiretroviral therapy on the development of CMV disease in HIV positive patients at high risk for CMV disease.
Verbraak FD; Boom R; Wertheim-van Dillen PM; van den Horn GJ; Kijlstra A; de Smet MD
Br J Ophthalmol; 1999 Oct; 83(10):1186-9. PubMed ID: 10502584
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus Viremia Associated With Increased Mortality in Cryptococcal Meningitis in Sub-Saharan Africa.
Skipper C; Schleiss MR; Bangdiwala AS; Hernandez-Alvarado N; Taseera K; Nabeta HW; Musubire AK; Lofgren SM; Wiesner DL; Rhein J; Rajasingham R; Schutz C; Meintjes G; Muzoora C; Meya DB; Boulware DR
Clin Infect Dis; 2020 Jul; 71(3):525-531. PubMed ID: 31504335
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus viremia in dried blood spots is associated with an increased risk of death in HIV-infected patients: a cohort study from rural Tanzania.
Brantsæter AB; Johannessen A; Holberg-Petersen M; Sandvik L; Naman E; Kivuyo SL; Rollag H; Bruun JN; Kvale D
Int J Infect Dis; 2012 Dec; 16(12):e879-85. PubMed ID: 23031419
[TBL] [Abstract][Full Text] [Related]
16. Declining levels of rescued lymphoproliferative response to human cytomegalovirus (HCMV) in AIDS patients with or without HCMV disease following long-term HAART.
Gerna G; Piccinini G; Genini E; Percivalle E; Zavattoni M; Lilleri D; Testa L; Comolli G; Maserati R; Baldanti F; Maccario R; Monforte AD; Revello MG
J Acquir Immune Defic Syndr; 2001 Dec; 28(4):320-31. PubMed ID: 11707667
[TBL] [Abstract][Full Text] [Related]
17. Correlates of change in cytomegalovirus viremia in patients with advanced human immunodeficiency virus infection who require transfusion.
Para MF; Kalish LA; Collier AC; Murphy EL; Drew WL;
J Infect Dis; 2001 Jun; 183(11):1673-7. PubMed ID: 11343218
[TBL] [Abstract][Full Text] [Related]
18. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.
Murphy EL; Collier AC; Kalish LA; Assmann SF; Para MF; Flanigan TP; Kumar PN; Mintz L; Wallach FR; Nemo GJ;
Ann Intern Med; 2001 Jul; 135(1):17-26. PubMed ID: 11434728
[TBL] [Abstract][Full Text] [Related]
19. Quantitation of cytomegalovirus (CMV) DNA by real-time PCR for occurrence of CMV disease in HIV-infected patients receiving highly active antiretroviral therapy.
Gourlain K; Salmon D; Gault E; Leport C; Katlama C; Matheron S; Costagliola D; Mazeron MC; Fillet AM; ;
J Med Virol; 2003 Mar; 69(3):401-7. PubMed ID: 12526052
[TBL] [Abstract][Full Text] [Related]
20. [The prognostic value of cytomegalovirus antigenemia and viremia for the development of cytomegalovirus disease and the survival of AIDS patients].
Cartón JA; Maradona JA; de Oña M; Asensi V; Melón S; García-Alcalde ML; Rodríguez-Junquera M; Moreno-Torrico A; de Zárraga M
Med Clin (Barc); 1999 Sep; 113(6):205-9. PubMed ID: 10472608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
